10x Genomics has announced a multi-project collaboration with Fred Hutchinson Cancer Center to use single cell and spatial biology technologies in cancer research, focusing on bladder cancer and acute myeloid leukemia. The projects aim to improve understanding of treatment responses and residual disease detection, potentially guiding more precise cancer therapies. This collaboration marks 10x Genomics' expansion into blood cancers and supports future diagnostic applications in oncology. The partnership also plans to develop clinical reporting frameworks to aid treatment planning for cancer patients.
As of Oct 07, 2026 20:11 WIB, 10x Genomics Inc (TXG) is trading at USD 78.10 on Pluang, down 3.17% for the day. The stock shows a balanced order activity with 54% Buy and 46% Sell, reflecting active investor interest. TXG's market cap stands at $10.51 billion, highlighting its significant presence in the health sector.
